Monday, December 02, 2019 8:21:56 AM
1) Target market is large. A person dies from CVDs every 38 seconds, more than from all oncology, cancer-related causes combined. Vascepa is directed toward providing a major advance in solving that problem by reducing that risk.
2) A sNDA is before the FDA, filed in late March 2019. A FDA AdCom was convened 11/14/2019; it recommended approval of an expanded label for Vascepa, 16-0. FDA’s pdufa date is on or before 12/28/2019. Major trade organizations/entities including ADA, AHA, ACC, NLA, Mayo Clinic echo that request for approval of an expanded label for Vascepa, adding Vascepa to the recommended SOCs of each.
3) Vascepa is currently priced far lower than other medications. Vascepa has not been the subject of price reductions emanating from any political party.
4) Prescriptions for Vascepa have obtained all-time highs in market share, necessarily from off-label scrips from the current niche label indication. I have had an off-label scrip for Vascepa since April 2013. With insurance and company card, I pay $36 out of pocket cost per year( $9 for a 3 month refill of that prescription).
5) I try to provide information from which other investors can invest or not. The decision to invest is up to each individual. I make no recommendations. Current share price targets range from $30 to over $50 per share. The basis for our shares is ~ $2.78. We hold > 100k shares.
Recent ACAD News
- Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences • Business Wire • 08/28/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 10:46:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 10:43:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 10:40:42 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 08/20/2024 08:39:26 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 08/20/2024 08:37:56 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 08/20/2024 08:35:57 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 08/20/2024 08:33:27 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 08/20/2024 08:31:27 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 08/20/2024 08:29:57 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 08/20/2024 08:27:51 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 08/20/2024 08:25:57 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 08/20/2024 08:23:55 PM
- Ryan Reynolds Announces More to Parkinson’s® Campaign • Business Wire • 08/14/2024 12:04:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 10:05:04 PM
- Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference • Business Wire • 08/07/2024 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 08:13:44 PM
- Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview • Business Wire • 08/06/2024 08:05:00 PM
- Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024 • Business Wire • 07/24/2024 08:05:00 PM
- Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med • Business Wire • 07/18/2024 01:04:00 PM
- Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting • Business Wire • 06/18/2024 01:04:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 10:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 10:00:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 10:00:16 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM